DrugPatentWatch Database Preview
Details for Patent: 6,500,454
Which drugs does patent 6,500,454 protect, and when does it expire?
This patent has fourteen patent family members in eleven countries.
Summary for Patent: 6,500,454
Title: | Timed, sustained release systems for propranolol |
Abstract: | A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration--time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations. |
Inventor(s): | Percel; Phillip J. (Troy, OH), Vishnupad; Krishna S. (Dayton, OH), Venkatesh; Gopi M. (Dayton, OH) |
Assignee: | Eurand Pharmaceuticals Ltd. (IE) |
Application Number: | 09/971,167 |
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; Device; Composition; Use; Delivery; |
Drugs Protected by US Patent 6,500,454
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ani Pharms Inc | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-001 | Mar 12, 2003 | BX | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Ani Pharms Inc | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-002 | Mar 12, 2003 | BX | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,500,454
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,040,086 | Timed, sustained release systems for propranolol | ➤ Try a Free Trial |
9,358,214 | Timed, sustained release systems for propranolol | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,500,454
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Norway | 335070 | ➤ Try a Free Trial | |||
Norway | 20041740 | ➤ Try a Free Trial | |||
Mexico | PA04003234 | ➤ Try a Free Trial | |||
South Korea | 101090719 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |